Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium

European Respiratory Journal

Volumn 19, Issue 2, 2002, Pages 209-216

  Vincken, W ^a   van Noord, J A ^a   Greefhorst, A P M ^a   Bantje, Th A ^a   Kesten, S ^a   Korducki, L ^a   Cornelissen, P J G ^a   van de Bosch, J M M ^a   Bunnik, M C M ^a   Creemers, J P H M ^a   Dalinghaus, W H ^a   Eland, M E ^a   Evers, W B M ^a   Gans, S J M ^a   Gooszen, H Ch ^a   van Harreveld, A J ^a   van Kasteren, J H L M ^a   Kuipers, A F ^a   Nossent, G D ^a   Pasma, H R ^a   Peters, A ^a   Pieters, W R ^a   Postmus, P E ^a   Schreurs, A J M ^a   Sinninghe Damste H E J ^a   Sips, A P ^a   van Spiegel, P I ^a   Westbroek, J ^a   Aumann, J L ^a   Janssens, E ^a   Pauwels, R ^a   Radermecker, M ^a   Slabbynck, H ^a   Stappaerts, I ^a   Verhaert, J ^a   Vermeire, P ^a   more..

^a UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

Author keywords

Chronic obstructive pulmonary disease; Dyspnoea; Exacerbations; Ipratropium; Quality of life; Tiotropium

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; IPRATROPIUM BROMIDE; PREDNISOLONE; SALBUTAMOL; STEROID; THEOPHYLLINE; TIOTROPIUM BROMIDE;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG USE; DRY POWDER; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; HOSPITALIZATION; HUMAN; LUNG FUNCTION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; METERED DOSE INHALER; PEAK EXPIRATORY FLOW; PREDICTION; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SCREENING TEST; SPIROMETRY; TREATMENT OUTCOME; XEROSTOMIA;

BRONCHODILATOR AGENTS; CHOLINERGIC ANTAGONISTS; DOUBLE-BLIND METHOD; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; IPRATROPIUM; MALE; MIDDLE AGED; PEAK EXPIRATORY FLOW RATE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; SCOPOLAMINE DERIVATIVES; VITAL CAPACITY;

EID: 18244368740     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.02.00238702     Document Type: Article

References (27)

1. Optimal assessment and management of chronic obstructive pulmonary disease (COPD)
2. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD)
3. Role of the parasympathetic system in airway obstruction due to emphysema
4. Tiotropium bromide (Ba 679 Br), a novel long-acting muscarinic antagonist for the treatment of obstructive airways disease
5. Tiotropium (Spiriva): Mechanistical considerations and clinical profile in obstructive lung disease
6. A randomised controlled comparison of tiotropium and ipratropium in the treatment of COPD
7. Lung volumes and forced ventilatory flows
8. The measurement of dyspnea: Contents, interobserver agreement, and physiologic correlates of two new clinical indexes
9. A self-complete measure of health status for chronic airflow limitation
10. The MOS 36-Item Short-Form Health Survey (SF-36)
11. Tiotropium bromide, a new long-acting antimuscarinic bronchodilator: A pharmacodynamic study in patients with chronic obstructive pulmonary disease (COPD)
12. Long-acting bronchodilation with once daily dosing of tiotropium (Spiriva™) in stable chronic obstructive pulmonary disease
13. Bronchodilator responses to anticholinergic and β-adrenergic agents in acute and stable COPD
14. Standard and double dose ipratropium bromide and combined ipratropium bromide and inhaled metaproterenol in COPD
15. Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease
16. Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD
17. Efficacy of salmeterol xinafoate in the treatment of COPD
18. Long-term metered-dose inhaler adherence in a clinical trial
19. Inhaled bronchodilators reduce dynamic hyperinflation during exercise in patients with chronic obstructive pulmonary disease
20. Quality of life changes in COPD patients treated with salmeterol
21. An empirical comparison of the St George's Respiratory Questionnaire (SGRQ) and the Chronic Respiratory Disease Questionnaire (CRQ) in a clinical trial setting
22. Respiratory viral infections in adults with and without chronic obstructive pulmonary disease
23. Survival experience of the population needing hospital treatment for asthma or COPD at age 50-54 years
24. Hospital and 1-year survival of patients admitted to intensive care units with acute exacerbation of chronic obstructive pulmonary disease
25. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease
26. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: The ISOLDE trial
27. 2-adrenergic agonist, salmeterol xinfoate, in patients with chronic obstructive pulmonary disease